Core Insights - Cosmos Health Inc. reported record financial results for Q3 2025, achieving the highest revenue, gross profit, and gross margin in its history, driven by strong performance across all core business segments [2][4][6] Financial Highlights - Q3 2025 revenue reached $17.11 million, a 38% increase from $12.41 million in Q3 2024, marking a new all-time high [4] - For the nine-month period ended September 30, 2025, revenue totaled $45.57 million, up 13% from $40.20 million in the prior-year period [4] - Gross profit for Q3 2025 increased 116% to $2.60 million, compared to $1.21 million in Q3 2024, the highest quarterly gross profit in the company's history [4] - Gross margin expanded to a record 15.21%, up from 9.72% a year earlier, reflecting improved efficiencies and a stronger sales mix [4] - Total operating expenses were $4.42 million in Q3 2025, compared to $3.45 million in Q3 2024, due to strategic investments in talent and new hires [4] Balance Sheet - Total assets increased to $69.49 million, up from $61.84 million as of June 30, 2025, reflecting enhanced liquidity and higher inventory levels [3][9] - Cash and cash equivalents rose sharply to $4.63 million from $0.66 million as of June 30, 2025, indicating significant improvement in financial flexibility [9] - Total liabilities increased to $46.36 million from $35.65 million as of June 30, 2025, due to the strategic utilization of a $300 million financing facility [9] Strategic Initiatives - The company secured a $300 million digital financing facility, enabling the build-up of a substantial digital assets portfolio and supporting long-term growth initiatives [6][9] - Cosmos Health is expanding its proprietary brands globally, including Sky Premium Life and C-Sept/C-Scrub, and has entered the U.S. market with local manufacturing [7][9] - The company signed a contract manufacturing agreement for the production of MYCOFAGYL pessaries, expanding its pharmaceutical portfolio into the gynecology segment [9]

Core Insights - Cosmos Health Inc. is at a pivotal moment, having refined its strategy and operations to foster sustainable growth and long-term value creation [1][3] - The company aims to create a global healthcare platform integrating various sectors, including pharmaceuticals, nutraceuticals, and digital finance [4][5] - The ambition for 2030 is to transform into a global powerhouse by scaling branded products and leveraging AI and blockchain technologies [6][7] Vision & Ambition - The company has aligned all business units towards a common goal of making high-quality healthcare accessible globally [4][5] - Cosmos Health emphasizes resilience, creativity, and leadership in rapidly evolving industries [5] Milestones & Achievements - Significant progress has been made in financing, manufacturing capabilities, and innovation pipeline, including securing a $300 million financing facility [9][11] - The company has expanded its manufacturing footprint and strengthened its wholesale operations [10][18] Financial Performance & Outlook - In 2024, Cosmos Health reported revenues of approximately $54.43 million, a 2% increase from 2023, with a notable reduction in operating expenses [40][41] - The company aims for continued growth and profitability, targeting approximately $155.8 million in revenue by 2027 [48][44] Strategy & Roadmap - The growth strategy is built on six pillars, focusing on profitability, cash flow, and scaling high-margin businesses [46] - The company is committed to maintaining financial strength while pursuing innovation and global expansion [49][52] R&D and Innovation - Cosmos Health is advancing its proprietary obesity treatment, CCX0722, and expanding its R&D pipeline across multiple therapeutic areas [25][30] - The company utilizes its AI-enabled platform, Cloudscreen, to enhance drug discovery and accelerate innovation [26][50] Global Expansion - The flagship brand, Sky Premium Life, is expanding internationally, with over 150 premium products and strong demand across various regions [18][19] - The company has established a dual manufacturing hub in the U.S. and Europe to enhance supply chain resilience [18][22] Insider Commitment - The CEO has invested over $18 million of personal capital into the company, demonstrating a strong alignment of interests with shareholders [34][35] Sustainability Commitment - Cosmos Health is focused on balancing growth with social responsibility, emphasizing innovation, market development, and digital asset strategies [53][54]

Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [6] - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union through its subsidiary Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices (GMP) [6] - Cosmos Health has established R&D partnerships targeting major health disorders and focuses on the R&D of novel patented nutraceuticals and innovative OTC products [6] Recent Developments - Cosmos Health's subsidiary, Sky Pharm SA, signed a distribution agreement with Scientific Pharmacy LLC for its Sky Premium Life food supplement products in Oman [1][3] - Scientific Pharmacy is a leading healthcare and beauty company in Oman, known for its strong customer focus and international brand partnerships [2] - The agreement includes an initial purchase order of 42,000 units, with Scientific Pharmacy managing all core activities related to the distribution and marketing of the products [3] Market Insights - The GCC nutraceuticals market was valued at $6.91 billion in 2024 and is projected to reach $15.5 billion by 2033, with a compound annual growth rate (CAGR) of 8.7% [4] - Growth in the nutraceuticals market is driven by rising health awareness, higher disposable incomes, government initiatives addressing lifestyle diseases, rapid urbanization, and the expansion of retail and e-commerce channels [4] Strategic Outlook - The CEO of Cosmos Health expressed excitement about the expansion into Oman, highlighting the potential for significant revenue generation supported by Scientific Pharmacy's established network [5] - The agreement is seen as a milestone that showcases the quality of Cosmos Health's products and the increasing global demand for the Sky Premium Life brand [5]

Core Insights - Cosmos Health Inc. has received an additional purchase order for 80,000 units of its Sky Premium Life products from Pharmalink in the UAE, following a successful sell-out of an initial order of 130,000 units [1][2] - The company aims to exceed 3 million units in cumulative orders over the first five years, supported by its exclusive distribution agreement with Pharmalink [2] - CEO Greg Siok highlighted the strong momentum of Sky Premium Life nutraceuticals in the UAE, emphasizing the effectiveness of the partnership with Pharmalink [3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, owning proprietary pharmaceutical and nutraceutical brands [3] - The company manufactures and distributes healthcare products, including pharmaceuticals, food supplements, and medical devices, through its subsidiary Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices [3] - Cosmos Health is expanding its global distribution platform throughout Europe, Asia, and North America, with established offices and distribution centers in Greece and the UK [3]

Core Insights - Cosmos Health Inc. reported a revenue increase of 2.0% to $54.43 million for FY 2024, driven by organic growth and contributions from prior acquisitions [5][12] - The company experienced a significant reduction in total operating expenses by 24.16% to $19.86 million, primarily due to cuts in general and administrative expenses and sales and marketing expenses [5][12] - Adjusted EBITDA was negative $3.73 million, a decline from positive $0.06 million in FY 2023, while adjusted net loss widened to $4.74 million from $0.81 million [5][12] Financial Performance - Revenue for FY 2024 was $54.43 million, up from $53.38 million in FY 2023 [5][12] - Gross margin decreased to 7.92% from 8.15% in FY 2023, attributed to a higher revenue mix from lower-margin logistics distribution [5] - Total operating expenses fell to $19.86 million from $26.18 million, with a 40.26% reduction in general and administrative expenses and a 71% decrease in sales and marketing expenses [5][12] Balance Sheet Overview - The liabilities-to-assets ratio was 55% at year-end 2024, indicating a balanced capital structure [3] - Total assets decreased by 17.72% to $54.31 million from $66.01 million at the end of 2023 [5][21] - Total liabilities slightly decreased by 0.64% to $29.78 million as of December 31, 2024 [5][21] R&D and Product Innovation - The company is leveraging AI-driven drug repurposing technologies and is advancing the commercialization of a proprietary weight loss drug [8] - Significant progress was made in securing long-term manufacturing agreements, enhancing revenue visibility [9] - The oncology portfolio was strengthened with the acquisition of two WIPO-patented anticancer drugs valued at over $24.5 million [11] Strategic Developments - The company expanded its nutraceutical brand, Sky Premium Life, with 60 new SKUs and launched the brand in Albania and Qatar [11] - A €2.2 million loan was secured against the CosmoFarm logistics center, providing strategic financial flexibility [10] - CEO Greg Siokas increased personal ownership by over 1 million shares, reflecting confidence in the company's long-term strategy [11]